F-1/A: Phaos Technology Holdings Files F-1/A for NYSE American IPO Amidst Significant Revenue Decline and Going Concern Doubts

Phaos Technology Holdings (Cayman) Limited has filed an amended F-1 registration statement for its initial public offering on the NYSE American, seeking to raise up to $13.5 million, despite reporting an 82.7% revenue decrease and a 31.5% increase in net loss for the six months ended October 31, 2024, raising substantial doubt about its ability to continue as a going concern.

Summary

• Phaos Technology Holdings (Cayman) Limited is an investment holding company that assembles and commercializes advanced microscopy solutions, technologies, and products, including super-resolution imagers capable of imaging down to 137nm.
• The company is offering 2,700,000 Class A Ordinary Shares, and selling shareholders are offering an additional 900,090 Class A Ordinary Shares, with an anticipated initial public offering price between US$4.00 and US$5.00 per share.
• The company expects to receive net proceeds of approximately US$11.24 million from its portion of the offering, which will be allocated to marketing (5%), product development (15%), supply chain expansion (20%), and general working capital (60%).
• For the six months ended October 31, 2024, revenue decreased by 82.7% to S$63,129 (US$47,720) from S$365,415 (US$276,217) in the prior comparable period, primarily due to a reduction in sales orders from largest customers.
• Net loss for the six months ended October 31, 2024, increased by 31.5% to S$2,019,092 (US$1,526,234) from S$1,535,175 (US$1,160,438) in the prior comparable period, driven by decreased revenue and increased employee benefits and other operating expenses.
• The company reported an accumulated deficit of S$9,049,158 (US$6,840,259) as of October 31, 2024, an increase of 45.8% from October 31, 2023.
• As of October 31, 2024, the company had a cash balance of S$231,655 (US$175,108) and incurred a negative cash flow from operations of S$1,928,899 (US$1,458,055), leading to substantial doubt about its ability to continue as a going concern.
• The company operates with a dual-class share structure, where Class A shares have one vote and Class B shares have three votes, and will be a controlled company post-IPO, with Beh Hook Seng controlling approximately 50.4% of total voting power.
• Phaos Technology has a patented microsphere-assisted technology and has obtained ISO 9001/14001/45001 certifications.
• The company has provided a loan of S$1,582,604 (US$1,196,290) to PT Neura Integrasi Solusi, an early-stage Indonesian company developing biomedical scanning software, with a risk of non-recovery.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including a sharp revenue decline and increased losses in the most recent six-month period, leading to an explicit 'going concern' warning. While it possesses patented technology, has strategic growth plans, and experienced management, the immediate financial performance and high customer concentration present substantial risks. The IPO is a capital raise, but the underlying financial health is concerning.

Positives

• The company possesses patented microsphere-assisted technology that significantly increases magnification of optical microscopes, allowing imaging down to 137nm, which is considered super-resolution in the optical industry.
• Phaos Technology offers integrated proprietary software with Artificial Intelligence (AI) components for pattern recognition, quality assurance/control, and diagnostics, complementing its hardware products.
• The company reported a substantial 189.3% increase in revenue for the full year ended April 30, 2024, reaching S$1,882,803 (US$1,380,848), indicating strong annual growth in product demand.
• Phaos Technology has an experienced management team with over two decades of expertise in the technology and engineering sectors, crucial for driving expansion and innovation.
• The company emphasizes turn-key solutions and reliable after-sales support, aiming to meet specific customer needs and ensure seamless customer experiences.
• Strategic growth plans include expanding into Southeast Asia, the Middle East, the United States, and Europe through joint ventures, strategic alliances, and enhanced marketing efforts.
• New product development initiatives are underway, including a new series of microsphere lenses with improved working distance, 3D analysis solutions, fully automated zoom microscopy, and digital pathology solutions for cancer cell analysis with AI components.
• The company is developing new AI and cloud computing capabilities in image processing, recognition, and anomaly detection to reduce manual workload and improve decision-making.
• Phaos Technology has secured ISO 9001/14001/45001 certifications, demonstrating a commitment to quality management, environmental management, and occupational health and safety.
• The company has received several prestigious industry awards, including the Titan Business Award for Most Innovative Company of the Year 2023 and the Stevie Award for Innovation in Technology Development in 2023.

Negatives

• The company experienced a significant 82.7% reduction in revenue for the six months ended October 31, 2024, compared to the same period in 2023, primarily due to reduced sales orders from its largest customers.
• Net loss increased by 31.5% for the six months ended October 31, 2024, reaching S$2,019,092 (US$1,526,234), and accumulated deficit grew by 45.8% to S$9,049,158 (US$6,840,259).
• The company has incurred operating losses and negative cash flow since inception, and its financial statements explicitly state "substantial doubt about our ability to continue as a going concern."
• There is a high customer concentration risk, with the top 5 customers accounting for 99.9% of total revenue for the six months ended October 31, 2024, and the largest customer alone accounting for 60%.
• The company provided a significant loan of S$1,582,604 (US$1,196,290) to PT Neura Integrasi Solusi, an early-stage company with limited operating history and revenue, posing a risk of non-recovery.
• The dual-class share structure, with Class B shares having three votes per share compared to Class A's one vote, concentrates voting power with the controlling shareholder (Beh Hook Seng, ~50.4% voting power post-IPO), limiting influence for other shareholders.
• As a controlled company and foreign private issuer, Phaos Technology may rely on exemptions from certain NYSE American corporate governance requirements, potentially affording less protection to public shareholders.
• Government grants, a component of other income, decreased significantly by 53.3% for the six months ended October 31, 2024, and by 67.8% for the year ended April 30, 2024, indicating a reduction in this revenue source.
• The company faces intense competition from larger, better-funded competitors with superior resources and broader product ranges, such as Keyence Corp., Nikon Corp., and Olympus Corp.

Risks

• The company is an early revenue stage company and has incurred operating losses and negative cash flow since inception, with no assurance of future profitability, raising substantial doubt about its ability to continue as a going concern.
• The company is susceptible to fluctuations in the prices and quantity of materials and components used in manufacturing microscopy equipment, which could negatively impact profitability.
• Major failures or malfunctions in microscopy equipment sold could adversely affect the company's reputation and profitability.
• A significant failure or deterioration in quality control systems could have a material adverse effect on business and operating results.
• The company may be affected if found in breach of any lease agreements, potentially incurring significant remediation costs, fines, or compensation.
• Increased competition in the microscopy equipment business in Singapore and the region may affect the company's ability to maintain market share and growth.
• The company is exposed to the credit risks of its customers, with average accounts receivable turnover days of approximately 208 days for the six months ended October 31, 2024, and a risk of non-payment.
• The business is subject to supply chain interruptions due to reliance on third-party logistics providers and component manufacturers, and geopolitical conflicts or pandemics could affect revenue and profitability.
• The company is exposed to risks arising from fluctuations of foreign currency exchange rates, which could affect the value of proceeds from share sales and dividend distributions.
• The company and/or its customers may not be able to obtain necessary approvals or certifications for the use of microscopy equipment in various jurisdictions.
• Negative publicity, particularly concerning product satisfaction or rumors, could harm the company's reputation and ability to attract and retain customers.
• Inability to maintain and protect intellectual property, or assertions of infringement by third parties, could adversely affect the business.
• The company is subject to risks related to product recalls, which could significantly impact operations, financial results, and reputation.
• The loan to PT Neura Integrasi Solusi for biomedical scanning software development carries a risk of non-recovery due to PT Neura's early stage, limited operating history, and financial risks.
• The dual-class share structure with different voting rights may adversely affect the value and liquidity of Class A Ordinary Shares and limit the ability of Class A shareholders to influence corporate matters.
• An active trading market for Class A Ordinary Shares may not be established or sustained, and the trading price may fluctuate significantly, potentially resulting in substantial losses for investors.
• The company may not maintain its listing on NYSE American, which could limit investors' ability to trade shares and subject the company to additional restrictions.
• The company may experience extreme volatility in its stock price, unrelated to actual operating performance, making it difficult for investors to assess value.
• Failure to implement and maintain an effective system of internal controls over financial reporting could lead to inaccuracies, non-compliance with reporting obligations, and fraud, adversely affecting investor confidence and share price.
• New investors will experience immediate and substantial dilution due to the public offering price being significantly higher than the net tangible book value per share.
• The initial public offering price may not be indicative of future trading prices, and market prices may be volatile.
• The controlling shareholder has substantial influence over the company, and their interests may not align with other shareholders, potentially preventing or causing changes of control.
• As a controlled company and foreign private issuer, the company may choose to exempt itself from certain corporate governance requirements, potentially affording less protection to public shareholders.
• Judgments obtained against the company or its auditor by shareholders may not be enforceable in the Cayman Islands or Singapore.
• As an emerging growth company, the company may take advantage of reduced reporting requirements, potentially limiting information available to investors.
• The company may lose its foreign private issuer status in the future, resulting in significant additional costs and expenses.
• The compensation of directors and officers may not be publicly available on an individual basis under Cayman Islands law, limiting transparency for public shareholders.
• The company will incur significantly increased costs and management time as a result of becoming a public reporting company.
• Future grants of employee share options and other share-based awards may result in significant share-based compensation expenses and dilute ownership interests.

Future Outlook

Phaos Technology Holdings plans to strengthen its market position in Singapore and Vietnam while progressively expanding into Southeast Asia, South Asia, the Middle East, the United States, and Europe. The company intends to broaden its marketing approach with a shift to digital marketing and participation in international exhibitions. Future product development includes improving working distance of microsphere lenses, 3D analysis solutions, fully automated zoom microscopy, and end-to-end hardware/software systems for digital pathology, including AI components for cancer cell analysis. The company also aims to build new technologies into existing products by augmenting with IoT and cloud computing solutions and providing calibration and certification services by Q2 2025. Management expects service revenue to contribute a greater percentage of total revenue going forward as product and software ranges grow.

Management Comments

• "We expect that the diversification of our customer base will allow us to increase and stabilize our product sales through a larger customer base and lower concentration of top customers which we are working actively to broaden."
• "As we grow our product and software range, we expect that service revenue will continue to contribute a greater percentage of our revenue going forward."
• "We believe that this is considered by the optical industry as a super resolution optical microscopy solution."
• "We believe in our strong corporate culture which emphasizes the creation of shareholder value."
• "We believe that we are well positioned to compete in the industry because of (i) our strong and stable relationships with our suppliers and customers, (ii) our experienced management team, (iii) our integrated software solutions within our product portfolio; (iv) our innovative and turn-key solutions; (v) our adaptive business model; and (vi) our reliable after-sales support."
• "We are confident that increased market penetration will result in exponential revenue generation, which will further assist PT Neura's ability to pay back the loan."

Industry Context

Phaos Technology operates in the growing and increasingly competitive microscopy equipment industry, specializing in advanced optical solutions that push beyond traditional optical limits (e.g., 137nm vs. 250nm). The integration of proprietary AI-powered software positions the company within the broader trend of digital transformation and automation in scientific research, quality control, and diagnostics. Its focus on turn-key solutions and after-sales support aligns with industry demands for comprehensive customer solutions. The expansion into biomedical and digital pathology, augmented by IoT and cloud computing, reflects a strategic move into high-growth segments within the healthcare and industrial sectors. The company competes with established global players like Keyence Corp., Nikon Corp., and Olympus Corp., which have greater scale and financial resources, necessitating its differentiation through patented technology and customized solutions.

Comparison to Industry Standards

• Phaos Technology's patented microsphere-assisted technology allows imaging down to 137nm, which is significantly beyond the 250nm optical limit of traditional optical microscopes, positioning it as a super-resolution optical microscopy solution. This capability is a key differentiator against competitors like Keyence Corp. (IM Series, VHX Series), Nikon Corp. (LV Series, ECLIPSE Series), Olympus Corp. (MX Series, DSX Series, CX Series), and Hirox Co. Ltd (HRX Series).
• The company's gross margin range of 20% to 40% for its product ranges suggests a competitive pricing strategy, which may be lower than some high-end specialized microscopy providers but aims to capture market share through turn-key solutions.
• The integration of in-house developed AI software for recognition patterns, QA/QC, and diagnostics provides an advanced feature set that enhances product performance and offers a competitive edge in versatility and adaptability, aligning with the industry's move towards smart lab solutions and automation.
• The company's expansion into digital pathology and collaboration with PT Neura Integrasi Solusi for biomedical scanning software, including AI components for cancer cell analysis, positions it in a rapidly evolving segment of the healthcare industry, where digital transformation is a key trend. PT Neura's participation in the Geneva-based Health Innovation Exchange (HIEX) and its valuation at US$5 million by HIEX, along with a sales pipeline of up to 300 integrated machine solutions, suggests a recognized potential in this niche, though PT Neura itself is early-stage and unprofitable.
• The development of Optical Coherence Tomography (OCT) technology in collaboration with a Korean leading microscopy company, co-sponsored by Singapore and Korean governments, indicates a commitment to advanced imaging techniques that offer both surface and penetration analysis, a capability that could set it apart in material science and industrial inspection applications.

Management Changes

Corporate Governance

Legal Proceedings

• As of the date of the prospectus, the company is not a party to any significant legal proceedings in Singapore or outside of Singapore.

Related Party Transactions

• The company has received advances from its major shareholder, TongHuai SG Enterprise Pte. Ltd., for business working purposes. The outstanding balance due to TongHuai SG Enterprise Pte. Ltd. was S$1,145,423 (US$865,825) as of October 31, 2024. These advances are interest-free, unsecured, and due on demand.
• On February 15, 2025, the company obtained a shareholder loan from TongHuai SG Enterprise Pte. Ltd. of S$1 million, with an additional option of S$1 million.

Stakeholder Impact

• **Shareholders**: New investors face immediate and substantial dilution. The dual-class share structure and controlled company status limit the voting power and influence of Class A shareholders. The 'going concern' warning indicates a high risk of investment loss. Existing shareholders' interests may not always align with the controlling shareholder's decisions.
• **Employees**: The company plans to hire additional personnel in sales, marketing, R&D, and operations, indicating potential job growth. An employee share incentive plan (2025 ESIP) is intended to incentivize performance and align interests, but share-based compensation expenses will decrease profitability.
• **Customers**: The company's focus on turn-key solutions, integrated software, and reliable after-sales support aims to enhance customer satisfaction. However, high customer concentration poses a risk if major customers reduce orders. The expansion into new regions and product lines aims to better serve diverse customer needs.
• **Suppliers**: The company emphasizes strong and stable relationships with key suppliers and adopts a diversification strategy for component procurement to mitigate price fluctuations and quantity issues. Supply chain interruptions remain a risk.
• **Creditors**: The company's 'going concern' doubt and negative cash flow from operations raise concerns about its ability to meet financial obligations. The loan to PT Neura Integrasi Solusi also presents a credit risk to the company.

Next Steps

• Complete the initial public offering and list Class A Ordinary Shares on the New York Stock Exchange American (NYSE American) under the symbol POAS.
• Utilize IPO net proceeds for marketing and promotion campaigns (5%), product development (15%), supply chain expansion (20%), and general working capital (60%).
• Continue regional expansion efforts in Southeast Asia, South Asia, the Middle East, the United States, and Europe through joint ventures, strategic alliances, and enhanced marketing.
• Further develop and improve existing product ranges, including new microsphere lenses with improved working distance, 3D analysis solutions, and fully automated zoom microscopy.
• Develop new product series for biomedical applications, specifically digital pathology for cancer cell analysis, and a new product range using Optical Coherence Tomography technology in collaboration with a Korean company (expected completion by December 31, 2026).
• Continue investing in AI and cloud computing capabilities for image processing, recognition, and anomaly detection.
• Begin providing calibration and certification services to existing and new customers by the second quarter of 2025.
• Actively work to broaden the customer base to increase and stabilize product sales and lower concentration of top customers.
• Implement and maintain an effective system of internal controls over financial reporting and address identified material weaknesses.
• Potentially issue up to 822,405 Class A Ordinary Shares under the 2025 Employee Share Incentive Plan (ESIP) to incentivize employees, directors, and consultants.

Key Dates

Recommendation

Keywords

Microscopy, Super-resolution imaging, Optical microscopes, AI software, Precision measurement, Magnification, Biomedical, Semiconductors, Manufacturing, Research & Development, Digital pathology, IPO, SEC filing, F-1/A, NYSE American, Cayman Islands, Singapore, Going concern, Dual-class shares, Controlled company, Intellectual property, Supply chain, Financial technology, Healthcare technology